WINDSOR MACHINES LIMITED
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Improving historical performance, but the outlook is too unquantified for a buy decision.
Hold: FY22 execution improved, with revenue up 18% and EBITDA up 28% to ₹37 crore from ₹29 crore, alongside ₹20 crore of bank-loan repayment and a ₹1 dividend.
However, this AGM offered no quantified FY23 guidance, margin targets, capacity utilization, or CapEx funding plan; management relied mainly on broad India-growth and capacity-expansion claims.
- Fy22 Results
- Injection Molding
- Extrusion
- Capacity Expansion
- Capex Funding
- Input Costs
Near term
Q1 FY23 standalone loss of ₹1.37 crore and pronounced quarterly seasonality could keep near-term earnings volatile.
Ferrous/non-ferrous inflation, freight costs, energy prices and semiconductor constraints remain margin risks; management provided no quantified sensitivity.
Investors need evidence that the stated FY23 sales target above prior-year performance is translating into orders, revenue and cash flow.
Longer term
Injection molding is becoming the growth engine, with management saying it represents roughly 70% of the broader market versus 10–15% for extrusion.
Management claims existing plants could generate more than ₹500 crore of turnover at full utilization, but current utilization and the investment required to reach it were not disclosed.
Product development in higher-tonnage injection, HDPE fittings, automotive, white goods, PVC/PE pipes and multilayer films could broaden the addressable market.
India-based manufacturing and China-plus-one demand are potential tailwinds, but the company did not quantify export opportunities, market share or competitive advantage.
Red flags
Shareholders repeatedly pressed for capacity utilization, turnover at full capacity, current-year CapEx and funding; management gave no figures beyond the greater-than-₹500 crore full-capacity claim.
The company said FY23 sales targets are above the prior two years' performance but did not provide a revenue, EBITDA, margin or order-book target.
Management acknowledged higher input costs and margin pressure from the Russia-Ukraine conflict, yet offered only generic cost-reduction assurances.
Competitive questions involving MACPOWER and G.G. Dandekar were not substantively addressed, leaving positioning and moat unclear.
The AGM contained no analyst-level challenge or detailed financial Q&A, limiting confidence in the forward read.
Recommendation history
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.